Spider Venom Peptide Pn3a Blocks Pain Calcium Channels and Enhances Low-Dose Opioid Effects
Spider venom peptide Pn3a inhibits ~55% of pain neuron calcium currents and works additively with sub-therapeutic opioids, explaining its pain relief at doses far above its Nav1.7 potency.
Quick Facts
What This Study Found
Pn3a inhibits ~55% of DRG HVA calcium currents and 60-80% of Cav1.2/1.3/2.1/2.2 channels; shows additive inhibition with sub-therapeutic opioids on shared calcium channel targets.
Key Numbers
10 uM Pn3a: ~55% HVA-ICa block; 60-80% Cav1.2/1.3/2.1/2.2 inhibition; Cav2.2 IC50=3.71 uM; 18mV hyperpolarizing inactivation shift; enhanced with DAMGO; no Cav2.3 effect
How They Did This
Whole-cell patch clamp electrophysiology in rat DRG neurons and HEK293 cells expressing individual Cav channels; IC50 determination for Cav2.2; voltage-dependence characterization; opioid co-application experiments.
Why This Research Matters
Understanding how spider venom peptides interact with opioid pathways could enable new pain treatments using low-dose opioid combinations — reducing addiction risk while maintaining pain relief.
The Bigger Picture
The opioid crisis demands new pain strategies. Venom peptides that enhance low-dose opioid effects could enable effective pain relief with dramatically reduced opioid doses and addiction risk.
What This Study Doesn't Tell Us
In vitro electrophysiology only; Pn3a concentrations needed are high (µM range); selectivity concerns with blocking multiple Cav channels; no in vivo pain model data in this study.
Questions This Raises
- ?Could Pn3a-like peptides enable opioid dose reduction in clinical pain management?
- ?Are there more selective Cav2.2 inhibitors from spider venoms?
- ?What are the cardiovascular risks of blocking Cav1.2 (cardiac calcium channel)?
Trust & Context
- Key Stat:
- 55% calcium current blocked Pn3a inhibited over half of high-voltage calcium currents in pain-sensing DRG neurons
- Evidence Grade:
- Moderate — rigorous electrophysiology study with clear mechanistic insights, but in vitro only.
- Study Age:
- Published in 2020; venom-derived analgesic peptides are an active drug development area.
- Original Title:
- Spider Venom Peptide Pn3a Inhibition of Primary Afferent High Voltage-Activated Calcium Channels.
- Published In:
- Frontiers in pharmacology, 11, 633679 (2020)
- Authors:
- McArthur, Jeffrey R, Munasinghe, Nehan R, Finol-Urdaneta, Rocio K, Adams, David J, Christie, Macdonald J
- Database ID:
- RPEP-04992
Evidence Hierarchy
Frequently Asked Questions
How could spider venom help with pain?
Spider venom contains peptides that block the same nerve channels involved in pain transmission. Pn3a blocks both sodium and calcium channels in pain neurons, shutting down pain signals.
Why combine with opioids?
By blocking pain calcium channels that opioids also target, Pn3a enhances opioid effects at very low doses — potentially providing pain relief with much less opioid and lower addiction risk.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04992APA
McArthur, Jeffrey R; Munasinghe, Nehan R; Finol-Urdaneta, Rocio K; Adams, David J; Christie, Macdonald J. (2020). Spider Venom Peptide Pn3a Inhibition of Primary Afferent High Voltage-Activated Calcium Channels.. Frontiers in pharmacology, 11, 633679. https://doi.org/10.3389/fphar.2020.633679
MLA
McArthur, Jeffrey R, et al. "Spider Venom Peptide Pn3a Inhibition of Primary Afferent High Voltage-Activated Calcium Channels.." Frontiers in pharmacology, 2020. https://doi.org/10.3389/fphar.2020.633679
RethinkPeptides
RethinkPeptides Research Database. "Spider Venom Peptide Pn3a Inhibition of Primary Afferent Hig..." RPEP-04992. Retrieved from https://rethinkpeptides.com/research/mcarthur-2020-spider-venom-peptide-pn3a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.